Renovos Biologics secures backing from Henley Business Angels and Orthopaedic Research UK to advance regenerative medicine technology.
The funding will support the clinical progression and regulatory advancement of the company proprietary nanoclay platform.
Renovos Biologics is a biotechnology company developing nanotechnology solutions to deliver therapeutic agents for tissue regeneration and wound healing.
Renovos Biologics has secured investment from members of Henley Business Angels alongside charity Orthopaedic Research UK to advance its proprietary regenerative medicine platform.
The biotechnology company is focused on improving outcomes for procedures such as spinal fusion through its flagship RENOVITE technology, a biodegradable nanoclay carrier designed to enhance drug retention at treatment sites.
The capital will be directed towards further development of the orthobiologics product and navigating key regulatory milestones to bring the treatment closer to clinical use.
From the founder
"advancing the development of [their] orthobiologics product, RENOVITE® nanoclay, and progressing through regulatory milestones to get this technology closer to clinic and spinal fusion patients."
Agnieszka Janeczek
Founder and CEO at Renovos Biologics
Investor perspective
"It has been a pleasure working with Agnieszka and her team on this investment round."
William Kilgallon
Lead Angel and Entrepreneur in Residence, Henley Business Angels
Use of funds
- 01Fund research and development
- 02Fund the next phase of growth
Investors
Categories
About the company
Renovos Biologics
Renovos Biologics develops targeted nanoclay carriers for regenerative medicine.